1 in 4 Have a Tirzepatide Advantage! Downsized News

Why does tirzepatide seem to work far better for some people than others? This week on The Downsized News, Laraine and Christopher Durham break down a new Mayo Clinic study that may offer part of the answer. Researchers identified a biological subtype of obesity found in about one in four participants who appeared to produce lower levels of naturally occurring appetite-regulating gut hormones. After six months on tirzepatide, the active ingredient in Mounjaro and Zepbound, this group lost an average of 21.5% of their body weight compared with 11.7% for everyone else in the study. The episode also looks at new Fractyl Health data on whether the Revita procedure could help people maintain weight loss after stopping tirzepatide, Novo Nordisk’s oral Wegovy approval in Europe, and new research into why food feels different on GLP-1 medications. Laraine and Christopher also cover Eli Lilly’s investment in Oura, a new study examining a rare potential vision risk associated with GLP-1 use, semaglutide and advanced liver disease, and the growing race to develop the next generation of obesity medications. The conversation includes today’s biggest GLP-1 and obesity brands, including Ozempic and Wegovy with semaglutide, Mounjaro and Zepbound with tirzepatide, and the newest oral GLP-1 option, Foundayo with orforglipron. They also explore experimental obesity drugs targeting entirely different biological pathways and the surprising arrival of Kalshi prediction markets that allow people to bet on clinical trial results and FDA decisions involving the pharmaceutical industry. Laraine and Christopher have been taking tirzepatide since September 2023 and have lost more than 150 pounds combined. They are not doctors, and nothing in this video is medical advice. The Downsized covers the latest GLP-1 news, obesity research, clinical trials, patient experiences, drug access and affordability, and developments from Eli Lilly, Novo Nordisk and the growing number of companies developing new treatments for obesity and metabolic disease. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. Get your Hume BodyPod today and use our exclusive Downsized code for up to 20% total savings! 👉 Use our Code: THEDOWNSIZED Link to purchase: https://humehealth.com//discount/THED... SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2026: https://thedownsized.org/downsized-at... DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 1 in 4 Have a Tirzepatide Advantage! Downsized News 01:59 Can You Keep the Weight Off After Stopping Tirzepatide? Fractyl Health Revita 06:42 Why Does Tirzepatide Work Better for Some People? Mayo Clinic Study 11:28 Novo Nordisk Oral Wegovy Approved in Europe 13:37 Why Does Food Feel Different on GLP 1s? 16:39 Eli Lilly Invests in Oura Ring 18:33 GLP 1s and Rare Vision Loss Risk Rutgers Study 21:53 Novo Nordisk Semaglutide and Advanced Liver Disease 23:48 Boehringer Ingelheim’s New Triple Agonist Obesity Drug 27:52 Mwyngil Therapeutics Develops Obesity Drugs Beyond GLP 1s 30:23 Kalshi Lets You Bet on Clinical Trial Results